ImmunoGen, Inc. (NASDAQ:IMGN) CEO Mark J. Enyedy sold 67,717 shares of the company’s stock in a transaction that occurred on Wednesday, February 21st. The shares were sold at an average price of $10.87, for a total value of $736,083.79. Following the completion of the sale, the chief executive officer now owns 532,383 shares in the company, valued at approximately $5,787,003.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
ImmunoGen, Inc. (IMGN) opened at $11.19 on Monday. ImmunoGen, Inc. has a twelve month low of $2.51 and a twelve month high of $12.05. The stock has a market capitalization of $1,480.00, a P/E ratio of -10.97 and a beta of 2.50. The company has a debt-to-equity ratio of -0.03, a current ratio of 2.81 and a quick ratio of 2.78.
ImmunoGen (NASDAQ:IMGN) last announced its quarterly earnings results on Friday, February 9th. The biotechnology company reported ($0.10) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.07) by ($0.03). The business had revenue of $39.40 million during the quarter, compared to the consensus estimate of $39.62 million. During the same period in the previous year, the firm earned ($0.39) earnings per share. The company’s revenue for the quarter was up 185.5% compared to the same quarter last year. equities research analysts predict that ImmunoGen, Inc. will post -1.09 EPS for the current fiscal year.
Large investors have recently made changes to their positions in the business. Arrowstreet Capital Limited Partnership acquired a new position in ImmunoGen in the second quarter valued at approximately $102,000. Intl Fcstone Inc. acquired a new position in shares of ImmunoGen during the 2nd quarter worth approximately $115,000. Raymond James Financial Services Advisors Inc. acquired a new position in shares of ImmunoGen during the 2nd quarter worth approximately $126,000. Virginia Retirement Systems ET AL acquired a new position in shares of ImmunoGen during the 3rd quarter worth approximately $136,000. Finally, SG Americas Securities LLC raised its stake in shares of ImmunoGen by 75.7% during the 4th quarter. SG Americas Securities LLC now owns 18,416 shares of the biotechnology company’s stock worth $118,000 after buying an additional 7,937 shares during the period. 70.99% of the stock is owned by institutional investors.
ILLEGAL ACTIVITY NOTICE: “ImmunoGen, Inc. (IMGN) CEO Sells $736,083.79 in Stock” was originally reported by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another site, it was stolen and republished in violation of US and international trademark & copyright laws. The original version of this article can be read at https://www.tickerreport.com/banking-finance/3222746/immunogen-inc-imgn-ceo-sells-736083-79-in-stock.html.
ImmunoGen Company Profile
ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.
Receive News & Ratings for ImmunoGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen and related companies with MarketBeat.com's FREE daily email newsletter.